SubHero Banner

Xofluza® (baloxavir marboxil) – Expanded indication

October 17, 2019 - Genentech announced the FDA approval of Xofluza (baloxavir marboxil), for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are: otherwise healthy, or at high risk of developing influenza-related complications.

Download PDF